Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-08-07
- Target Recruit Count
- 800
- Registration Number
- NCT00070278
- Locations
- π¬π§
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: isotretinoinDrug: melphalanDrug: topotecan hydrochlorideDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00070200
- Locations
- πΊπΈ
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
πΊπΈChildren's Memorial Hospital - Chicago, Chicago, Illinois, United States
π¦πΊWestmead Hospital, Westmead, New South Wales, Australia
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: pegfilgrastimDrug: AC regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: paclitaxel
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 3294
- Registration Number
- NCT00070564
- Locations
- πΊπΈ
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
πΊπΈCancer Care Associates - Norman, Norman, Oklahoma, United States
πΊπΈRiverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: CyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateRadiation: radiation therapyBiological: Yttrium-90 ibritumomab tiuxetanBiological: Indium-111 ibritumomab tiuxetan
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 46
- Registration Number
- NCT00070018
- Locations
- πΊπΈ
Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States
πΊπΈProvidence Cancer Center, Anchorage, Alaska, United States
πΊπΈCCOP - Greenville, Greenville, South Carolina, United States
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas
- Conditions
- Lymphoma
- First Posted Date
- 2003-09-24
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00003113
- Locations
- πΊπΈ
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00002638
- Locations
- πΊπΈ
University of Nebraska Medical Center, Omaha, Nebraska, United States
S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
- Conditions
- Breast CancerMenopausal SymptomsInfertility
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 257
- Registration Number
- NCT00068601
- Locations
- π¦πΊ
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
π¦πΊRoyal Hobart Hospital, Hobart, Tasmania, Australia
π¦πΊMonash Medical Center - Clayton Campus, Clayton, Victoria, Australia
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
- Conditions
- LymphomaMyelodysplastic/Myeloproliferative DiseasesMultiple Myeloma and Plasma Cell NeoplasmChronic Myeloproliferative DisordersLeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00068523
- Locations
- πΊπΈ
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
- Conditions
- Cardiac ToxicityInflammatory Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Breast Cancer
- Interventions
- Drug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: paclitaxelBiological: trastuzumabProcedure: therapeutic conventional surgeryRadiation: radiation therapyDrug: tamoxifen citrateOther: laboratory biomarker analysis
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 396
- Registration Number
- NCT00016276
- Locations
- πΊπΈ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- Chronic Myeloproliferative DisordersLymphomaMultiple Myeloma and Plasma Cell NeoplasmLeukemiaPrecancerous/Nonmalignant ConditionSmall Intestine CancerMyelodysplastic Syndromes
- First Posted Date
- 2003-08-28
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005804
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.